Health TrialsbyHealthPanel

A Phase Ib Study of the Selective PKC-β Inhibitor MS-553 in Patients With Refractory or Relapsed CLL/SLL

ConditionsCLL (Chronic Lymphocytic Leukemia)SLL (Small Lymphocytic Lymphoma)
Trial statusNot yet recruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorMingSight Pharmaceuticals, Inc

About this trial

A Phase Ib Study of the Selective PKC-β Inhibitor MS-553 in Patients with Refractory or Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age 18 years or older.

History of histologically documented CLL or SLL that meets iwCLL diagnostic criteria according to the 2018 guidelines, and

Indication for treatment as defined by the 2018 iwCLL guidelines, or the need for disease reduction prior to allogeneic transplantation.-

Disqualifiers

Current transformation of CLL/SLL non-Hodgkin lymphoma or Hodgkin lymphoma.

Active and uncontrolled autoimmune cytopenia(s).

Trial design

Design model

Parallel

Treatments tested in this trial

  • MS-553, DS1

    Drug

    Oral, Dose Schedule 1

  • MS-553, DS2

    Drug

    Oral, Dose Schedule 2

Treatment groups

12 Participants
are divided into 2 treatment groups
Group A: MS-553, dose schedule 1 (DS1)Experimental treatment 1 intervention
Group B: MS-553, dose schedule 2 (DS2)Experimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

The occurrence of AEs and SAEs, with abnormal laboratory tests results, abnormal physical examination findings, abnormal vital signs, and abnormal ECG readings

Time frame
Through study completion, an average of 2 years

Secondary outcomes

Other outcomes

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

MingSight Pharmaceuticals, Inc

Lead sponsor

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: